Huseman C A, Colombo J L, Brooks M A, Smay J R, Greger N G, Sammut P H, Bier D M
Department of Pediatrics, University of Nebraska Medical School, Omaha 68198-5180, USA.
Pediatr Pulmonol. 1996 Aug;22(2):90-5. doi: 10.1002/(SICI)1099-0496(199608)22:2<90::AID-PPUL2>3.0.CO;2-N.
The purpose of this study was to determine whether GH treatment of cystic fibrosis (CF) patients can result in an anabolic effect, i.e., increased weight gain, improved growth rate, nitrogen retention, and improved pulmonary function. Nine prepubertal endocrinologically normal CF patients (3 girls, 6 boys; chronological age (CA) 5.5-9.8 years, and bone age (BA) 4.5-9.0 years), received recombinant human growth hormone (rhGH) 0.3 mg/kg/week subcutaneously for a period of 12 months (N = 8) or 9 months (N = 1). Normal glucose tolerance was determined before treatment. Pulmonary function studies and anthropometric measurements were done every 3 months. Thyroid status, somatomedin C (SmC), BA, and routine chemistries were evaluated every 6 months. The pretreatment growth velocity averaged 5.7 +/- 0.3 (SE) cm/year and significantly increased to 7.8 +/- 0.4 (SE) cm/year during therapy, (P < 0.01). Standard deviation scores (SDS) for height significantly increased during rhGH therapy as compared with pretreatment, (P < 0.05). Weight of the patients during rhGH therapy did not significantly change during or after rhGH therapy. After therapy, all patients showed a significant increase in arm muscle area (AMA) and a significant decrement in arm fat area (AFA) (P < 0.01). Net nitrogen anabolism was negative in all subjects before therapy but became more positive in five patients during rhGH therapy. Three patients achieved positive nitrogen retention. SmC values significantly increased from a mean value of 0.62 +/- 0.1 (SE) U/ml to 1.6 +/- 0.6 (SE) U/ml after therapy. BA advanced 1.0 +/- 0.1 SE per year after treatment. Of the seven patients able to perform adequate pulmonary function testing, improvement occurred in FVC, FEV1.0, and PEFR in 5, 5, and 4 patients, respectively, but these changes did not reach statistical significance. We conclude that biosynthetic rhGH therapy had a significant anabolic effect in CF patients as shown by increased growth velocity, SmC values, increased protein and decreased fet stores, and a positive or less negative net nitrogen retention in five of the patients.
本研究的目的是确定生长激素(GH)治疗囊性纤维化(CF)患者是否能产生合成代谢效应,即增加体重增加、提高生长速率、改善氮潴留以及改善肺功能。9名青春期前内分泌正常的CF患者(3名女孩,6名男孩;实际年龄(CA)5.5 - 9.8岁,骨龄(BA)4.5 - 9.0岁),皮下注射重组人生长激素(rhGH)0.3 mg/kg/周,持续12个月(N = 8)或9个月(N = 1)。治疗前测定正常糖耐量。每3个月进行一次肺功能研究和人体测量。每6个月评估甲状腺状态、生长介素C(SmC)、骨龄和常规化学指标。治疗前生长速度平均为5.7±0.3(SE)cm/年,治疗期间显著增加至7.8±0.4(SE)cm/年,(P < 0.01)。与治疗前相比,rhGH治疗期间身高标准差评分(SDS)显著增加,(P < 0.05)。患者体重在rhGH治疗期间及治疗后均无显著变化。治疗后,所有患者的上臂肌肉面积(AMA)显著增加,上臂脂肪面积(AFA)显著减少(P < 0.01)。治疗前所有受试者的净氮合成代谢均为阴性,但rhGH治疗期间5名患者的净氮合成代谢变得更积极。3名患者实现了正氮潴留。治疗后SmC值从平均值0.62±0.1(SE)U/ml显著增加至1.6±0.6(SE)U/ml。治疗后骨龄每年提前1.0±0.1 SE。在7名能够进行充分肺功能测试的患者中,分别有5名、5名和4名患者的用力肺活量(FVC)、第1秒用力呼气容积(FEV1.0)和呼气峰值流速(PEFR)有所改善,但这些变化未达到统计学意义。我们得出结论,生物合成rhGH治疗对CF患者有显著的合成代谢效应,表现为生长速度增加、SmC值升高、蛋白质增加和脂肪储存减少,以及5名患者的净氮潴留为正或负性减弱。